DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible
December 12, 2017
December 12, 2017
ATLANTA, Georgia, Dec. 12 -- Johnson and Johnson issued the following news release:
Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX(R) (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem ce . . .
Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX(R) (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem ce . . .